Welcome!

Open Source Authors: Michelle Drolet, Ignacio M. Llorente, Shelly Palmer, Si Chen, RealWire News Distribution

News Feed Item

University of Sussex Selects Dotmatics' Studies Notebook to Assist their Drug Discovery Research

BISHOP'S STORTFORD, England, January 13, 2014 /PRNewswire/ --

The Translational Drug Discovery Group at the University of Sussex enhance their use of the Dotmatics Platform with the addition of Dotmatics' ELN, Studies Notebook


Dotmatics, a leading provider of scientific informatics solutions and services to the pharmaceutical and biotechnology industries, is pleased to announce today that the Translational Drug Discovery Group at the University of Sussex has selected Dotmatics' fully searchable and web-based Electronic Laboratory Notebook, Studies Notebook, to complement their existing Dotmatics data management platform. The Translational Drug Discovery group is a multidisciplinary research group with integrated teams of in vitro biologists and medicinal chemists. The group is undergoing a process of rapid expansion with a portfolio of projects from hit identification to lead optimisation and consequently generates a large volume of complex and diverse data.

Dotmatics' Studies Notebook is a highly configurable and versatile Electronic Laboratory Notebook designed to cover all scientific disciplines. It is exceedingly effective in academic institutes as it facilitates the continuity of research across generations of researchers as well as the collaborative research of scientists working across multiple disciplines. "Incorporating the Dotmatics software suite into our projects has enabled us to work very effectively and to process and analyse data in a highly efficient manner," said Simon Ward, Professor of Medicinal Chemistry & Director of Translational Drug Discovery Group.

"The recent addition of the Dotmatics Electronic Laboratory Notebook offers a fully optimised and perfectly integrated addition to our existing chemoinformatics platform," said John Atack, Professor of Molecular Pharmacology & Director of Translational Drug Discovery Group. "In combination with Browser, Register and Vortex, Studies Notebook enables us to access all of our data in a single web-based platform and allows our scientists to streamline their data entry, triage and analysis thus improving the efficiency of our research."

"The Translational Drug Discovery Group at the University of Sussex is expanding rapidly and as such required a scalable, integrated and optimised suite to capture their research whilst making the data readily accessible and searchable. The high level of customisation of Studies Notebook enables the group to share data with collaborators whilst keeping proprietary data secure," added Dr Stephen Gallagher, CEO of Dotmatics.

About Dotmatics:

Dotmatics is a leading global scientific informatics software and services provider, delivering solutions tailored to the modern, highly collaborative and mobile pharmaceutical, biotechnology and chemical industries as well as academia. Dotmatics' enterprise solutions are flexible, scalable and configurable, providing effective scientific information management across entire organizations, from discovery research to development and early manufacturing. Dotmatics has significant expertise in scientific informatics, including database management for chemistry and biologics, electronic laboratory notebooks, chemical and biological registration, screening data management, SAR analysis, reporting, and visualization. Dotmatics solutions are available for local or cloud deployment and they are supported on Microsoft Windows, Mac OS X and Linux.  A privately owned company, Dotmatics was founded in 2005 and their headquarters is based south of Cambridge in the UK.

Enquiries:
Mariana Vaschetto
Dotmatics Limited
Tel (Europe): +44(0)1279-654-123
Tel (US West Coast): +1(619)419-2808
Tel (US East Coast): +1(781)281-2330
Fax: +44(0)1279-653-088
Email: [email protected]
Website: http://www.dotmatics.com



SOURCE Dotmatics Ltd

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.